ArticleContraception and reproductive medicine2025
Acceptability of and preferences for long-acting injectable hormonal contraception among US women: evidence from a national cross-sectional online survey.
Article in Contraception and reproductive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLong-acting injectable (LAI) hormonal contraception offers a promising approach to meet women's pregnancy prevention needs. We sought to understand acceptability of and preferences for LAI hormonal contraception among US women, to optimize the design of a sustained-release LAI in development - including which durations to pursue.
methodsWe implemented a national cross-sectional online survey including a discrete choice experiment (DCE) with women ages 18-44 years currently using or interested in using contraception. Recruitment was via Prime Panels. DCE attributes included potential duration of effectiveness (6/12/24-months), effect on menses, side effects, and timing of return-to-fertility after use. We used mixed-multinomial logit models to analyze the data.
resultsWomen (n = 1,029) were 28.6 years old on-average, from 49 US states. 30.9% were Black/African American; 11.6% Hispanic/Latina. 71.6% were nulliparous; 49.0% did not want a(nother) child. Common current contraceptive methods were birth control pills (37.4%), male condoms (35.7%), and withdrawal (19.8%); 18.9% reported having had an unintended pregnancy. In the DCE, women had strong negative preferences for: may cause heavier/unpredictable periods, mild headaches/nausea, slight weight gain, and delayed return-to-fertility (6-12 vs. 3 months), and positive preferences for: may cause no period, and shorter/lighter periods (all p < 0.001). Women also preferred the 12-month to the 6-month duration (p = 0.03). When asked directly about their interest in an LAI with no/minimal side effects/effects on menses and quick return-to-fertility, 92.4% expressed interest, with two-thirds preferring a longer duration (12 or 24-months), and one-third the 6-month duration. Preference for the 6-month duration (vs. 12 or 24) was most highly associated with wanting a child within five years, and higher discomfort with hormones (both p < 0.001).
conclusionsUS women report high interest in an LAI. Interest substantially decreases if the LAI may cause unwanted effects such as heavier/unpredictable periods, mild headaches/nausea, slight weight gain, or delayed return-to-fertility. While longer duration (12 + months) is preferred overall, having a 6-month option appears important especially for women who may want to get pregnant within the next few years, and those concerned about hormones (to try it before using a longer duration).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.